Previous studies have shown that the HRQoL of patients with cluster headache is impaired. Although the severity of the cluster headache attacks might predict considerable functional and social disabilities during the active period of patients with cluster headache, little is known about the predictors associated with their HRQoL and overall impact on physical and social functioning.
The Korean Cluster Headache Registry is a prospective, observational study that included patients with cluster headache from 16 headache clinics in South Korea, enrolled from September 2016 to February 2021. This study aimed to evaluate the impact of cluster headache on physical and social functioning and to identify factors affecting HRQoL in patients with cluster headache during their active periods. The questionnaire consisted of questions about patientsâ HRQoL using European Quality 5-Dimensions 5-Levels (EQ-5D-3L). Dr Soo-Kyoung Kim (Gyeongsang National University, South Korea) shared the results.
Included were 425 patients with cluster headache during an active period, as well as age- and sex-matched contrast groups, consisting of patients with migraine and healthy controls. The cluster headache patients had lower median scores of EQ-5D-3L than healthy controls and migraine patients (0.88, 0.99, and 0.99, respectively; P<0.001). In total, 58 (13.6%) patients with cluster headache had a moderate-to-severe impairment of their HRQoL. The HRQoL scores in cluster headache patients were associated with:
- current smoking status;
- severity, frequency, and duration of pain; and
- scores on several questionnaires: Generalized Anxiety Disorder (GAD)-7, Patient Health Questionnaire (PHQ)-9, Headache Impact Test (HIT)-6, and the 12-item Allodynia Symptom Checklist (ASC-12) scores.
Multivariate logistic regression analyses revealed that HRQoL in cluster headache patients was negatively correlated with the daily frequency of headache, duration of active periods, GAD-7, and PHQ-9 scores.
- Kim S-K, et al. Predictors of health-related quality of life in patients with cluster headache during the active periods using the time trade-off method. AL067, IHC 2021, 8â12 September.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Dry eye disease is more prevalent in migraine Next Article
Migraine may not be a risk factor for stroke »
« Dry eye disease is more prevalent in migraine Next Article
Migraine may not be a risk factor for stroke »
Table of Contents: IHC 2021
Featured articles
Letter from the Editor
COVID-19
Telemedicine beneficial for headache care during the pandemic
Comparison of headaches after SARS-CoV-2 vaccination
Grey matter cortical changes in patients with persistent headache after COVID-19
Increased risk of cerebral venous thrombosis in COVID-19
Patient Perception and Symptoms
Predictors of health-related quality of life in cluster headache
Dry eye disease is more prevalent in migraine
Voice change and throat swelling are cranial autonomic symptoms in primary headache
Association between physical inactivity and headache disorders
Increased suicidal attempts and risks of ideation in medication-overuse headache
Cardioembolic Comorbidities
AI-enabled ECG algorithm predicts atrial fibrillation risk in migraine
Migraine may not be a risk factor for stroke
Imaging
Functional brainstem somatotopy of the trigeminal nerve during nociception
Morphological changes in cluster headache between attacks
Interictal pontine metabolism in migraine patients without aura
Genome-Wide Association Studies
Largest genome-wide association study of migraine to date
Robust evidence that cluster headache has a genetic basis
Pharmacological Treatment
Insights in drug-drug interactions facilitate rational polypharmacy
Rimegepant confers long-term improvements in MMDs
First real-world effectiveness data of erenumab is promising
Galcanezumab effective in patients with episodic or chronic cluster headache
Central effects and affected somatosensory processing with galcanezumab in migraine
Long-term safety and tolerability of atogepant in migraine
Non-Pharmacological Treatment
Occipital nerve stimulation effective and safe in chronic cluster headache
Related Articles
October 27, 2020
Real-world evidence reveals physiciansâ perception of erenumab
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com